- 基本信息
|
导师姓名：
|
蒋华
|
学科代码：
|
100214
|
|
|
性别：
|
女
|
学科名称：
|
肿瘤学
|
|
培养单位：
|
附属仁济医院
|
三级学科
|
|
|
导师类型：
|
博士生导师
|
专业领域名称：
|
|
|
联系方式：
|
上海市徐汇区斜土路2200弄25号
|
专业领域代码：
|
|
|
邮编：
|
200032
|
邮箱地址：
|
jianghuapy@163.com
|
- 研究方向 (点击浏览详细信息)
- 社会任职
| |
|
细胞工程与转基因生物分会委员
|
|
上海市免疫学会肿瘤免疫专业委员会委员
|
|
上海市免疫学会第十二届理事会理事
|
- 科研项目
| 81871918 | 孤核受体NR2F6对靶向磷脂酰肌醇蛋白聚糖-3的CAR-T细胞 | 国家自然基金，面上项目 |
2019-01~2021-12
|
57万元
| 课题负责人 |
| 18431902900 | 高度肿瘤特异性的抗EGFR/EGFRvIII双靶向CAR-T细胞的临床前研究 | 上海市科学技术委员会创新支撑项目 |
2018-04~2021-06
|
70万元
| 课题负责人 |
| 201740124 | 敲除孤核受体NR2F6对嵌合抗原受体修饰的T细胞抗实体瘤疗效的影响及机制 | 上海市卫计委面上项目 |
2018-01~2020-12
|
10万元
| 课题负责人 |
| 81372468 | 抗表皮生长因子受体突变体III的单克隆抗体CH12对肿瘤细胞自噬作用及机制研究 | 国家自然基金，面上项目 |
2014-01~2017-12
|
75万元
| 课题负责人 |
| 13QA1403300 | 靶向EGFR隐蔽表位的嵌合抗原受体基因修饰的T细胞对脑胶质瘤的治疗研究 | 上海市科技人才计划项目启明星计划（A类） |
2013-07~2015-06
|
20万元
| 课题负责人 |
| 12JC1408300 | 抗表皮生长因子受体抗体CH12 用于喉癌的药效学及其个体化用药标志物的研究 | 上海市科委基础研究重点项目 |
2013-01~2015-12
|
40万元
| 课题负责人 |
| 2012ZX10002015-007 | 抗表皮生长因子受体新型单抗的临床前药效学研究 | 国家“十二五”科技重大专项 |
2012-01~2015-12
|
123.1万元
| 课题负责人 |
| 30901820 | 表皮生长因子受体突变体III(EGFRvIII)对肝癌的5-氟尿嘧啶抗性的作用机制及对策 | 国家自然基金，青年科学基金项目 |
2010-01~2012-12
|
21万元
| 课题负责人 |
- 学术论文
|
, Zhimin Shi#, Peng Wang, Cong Wang, Linlin Yang, Guoxiu Du, Honghong Zhang, Bizhi Shi, Jie Jia, Qixiang Li, Huamao Wang, Zonghai Li*
|
Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer
|
J Natl Cancer Inst
|
2019
|
111(4):409-418
|
|
Dong Q, Shi B, Zhou M, Gao H, Luo X, Li Z,
|
Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12
|
Front Med
|
2019
|
13(1):83-93
|
|
Xiuqi Wu, Hong Luo, Bizhi Shi, Shengmeng Di, Ruixin Sun, Jingwen Su, Ying Liu, Hua Li,, Zonghai Li*
|
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
|
Mol Ther
|
2019
|
27(8):1483-1494
|
|
Chen M, Sun R, Shi B, Wang Y, Di S, Luo H, Sun Y, Li Z, Zhou M,
|
Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII expressing glioblastoma in C57BL/6 mice
|
Biomed Pharmacother
|
2019
|
113:108734
|
|
Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z*,
|
Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma
|
J Immunol
|
2019
|
203 (1):198-207
|
|
Wen Xu, Fei Song, Biao Wang, Kesang Li, Mi Tian, Min Yua, Xiaorong Pan, Bizhi Shi, Jianwen Liu, Jianren Gu, Zonghai Li,
|
The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III
|
Cell Physiol Biochem
|
2018
|
46: 226-237
|
|
, Huiping Gao, Juan Kong, Bo Song, Peng Wang, Bizhi Shi, Huamao Wang and Zonghai Li*
|
Selective targeting of glioblastoma with EGFRvIII/EGFR bi-targeted chimeric antigen receptor T cell
|
Cancer Immunol Res
|
2018
|
6(11):1314-1326
|
|
Yanyu Bi# Hua Jiang#,, Bo Song, Huamao Wang, Xianming Kong and Zonghai Li
|
Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
|
Oncotarget
|
2017
|
8:52866-52876
|
|
, Bo Song, Peng Wang, Bizhi Shi, Qixiang Li, Mingliang Fan, Shengmeng Di, Jie Yang, Zonghai Li*
|
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells
|
Protein & Cell
|
2017
|
8(12): 926–931
|
|
Xiuqi Wu, Bizhi Shi, Jiqin Zhang, Zhimin Shi, Shengmeng Di, Minliang Fan, Huiping Gao, Hai Wang, Jianren Gu,, Zonghai Li
|
A fusion receptor as a safety switch, detection and purification biomarker for adoptive transferred T cells
|
Mol Ther
|
2017
|
25(10): 2270-2279
|
|
Wen Xu, Yanyu Bi, Juan Kong, Jiqin Zhang, Biao Wang, Kesang Li, Mi Tian, Xiaorong Pan, Bizhi Shi, Jianren Gu,, Xianming Kong*, Zonghai Li*
|
Combination of CH12 with Rapamycin Synergistically Inhibits the Growth of GFRvIII+PTEN- Glioblastoma in Vivo
|
Oncotarget
|
2016
|
7(17):24752-65
|
|
, Qiongna Dong#, Xiaoying Luo, Bizhi Shi, Huamao Wang, Huiping Gao, Juan Kong, Jiqin Zhang, Zonghai Li.
|
The Monoclonal Antibody CH12 Augments 5-Fluorouracil-Induced Growth Suppression of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III
|
Cancer Letters
|
2014
|
342(1):113-120
|
|
Yaqiong Yang#,, Huiping Gao, Juan Kong, Pengwei Zhang, Suwen Hu, Bizhi Shi, Pengfei Zhang, Ming Yao and Zonghai Li*
|
The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III
|
Neoplasia
|
2012
|
14(6):509-518
|
|
, Huamao Wang, Zhonghua Tan, Suwen Hu, Hai Wang, Bizhi Shi, Lin Yang, Peiyong Li, Jianren Gu, Hongyang Wang, and Zonghai Li*
|
Growth Suppression of Human Hepatocellular Carcinoma Xenografts by a Monoclonal Antibody CH12 Directed to Epidermal Growth Factor Receptor Variant III
|
J Biol Chem
|
2011
|
286(2):5913-5920
|
|
, Hua Jiang#, Cuizhen Zhang#, Huamao Wang, Lin Yang, Yongfeng Yu, Junming Yu, Bizhi Shi, Zhijun Shen, Huiping Gao, Zhiwei Chen, Shujun Tian, Shun Lu, Zonghai Li*, and Jianren Gu.
|
Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer
|
Biomarkers
|
2010
|
15(2):128-134
|
|
Huamao Wang#,, Min Zhou, Zhibing Xu, Shiguo Liu, Bizhi Shi, Xiao Yao, Ming Yao, JianRen Gu, Zonghai Li*
|
Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma
|
Cancer Letters
|
2009
|
279():30-38
|
|
, Xiu-mei Cai, Bi-zhi Shi, Jie Zhang, Zong-hai Li*, Jian-ren Gu*
|
Development of efficient RNA interference system using EGF-displaying phagemid particles
|
Acta Pharmacol Sin
|
2008
|
29(4):437-442
|
|
, Jie Zhang, Bi-zhi Shi, Yu-hong Xu, Zonghai Li*, Jianren Gu*
|
Application of EGFP-EGF fusions to explore the mechanism of endocytosis of epidermal growth factor
|
Acta Pharmacol Sin
|
2007
|
28(1):111-117
|
|